Targeting NPC1 in Renal Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Rapidly proliferating cancer cells, including clear cell renal cell carcinoma (ccRCC), exhibit increased cholesterol requirements.
• Tumor cells often rely on external lipid sources due to limitations in endogenous cholesterol synthesis pathways.
• Understanding cholesterol acquisition mechanisms in ccRCC is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the mechanisms of cholesterol acquisition in ccRCC cells.
• To determine the role of lipoproteins (LDL, HDL, VLDL) in supporting ccRCC growth and TKI resistance.
• To elucidate the intracellular trafficking pathways of exogenous cholesterol and the involvement of NPC1.

Main Methods:

• Analysis of ccRCC cell growth supported by various lipoproteins.
• Assessment of lipoprotein effects on tyrosine kinase inhibitor (TKI) efficacy.
• Investigation of intracellular cholesterol trafficking using NPC1-dependent pathways.
• Quantification of NPC1 expression at mRNA and protein levels in ccRCC.

Main Results:

• LDL, HDL, and VLDL equally support ccRCC cell growth and counteract TKI antitumor effects.
• Lipoprotein-derived cholesterol traffics via an NPC1-dependent endosomal system, distinct from endogenously synthesized cholesterol.
• NPC1 expression is upregulated in ccRCC and correlates with poor patient prognosis.

Conclusions:

• ccRCC cells possess redundant cholesterol acquisition mechanisms, utilizing multiple lipoproteins.
• NPC1 plays a critical role in the intracellular trafficking of exogenous cholesterol in ccRCC.
• Targeting NPC1-mediated endolysosomal cholesterol export presents a potential therapeutic strategy for ccRCC.